ENTRY       D09966                      Drug
NAME        Talimogene laherparepvec (USAN);
            Talminogene laherparepvec;
            Imlygic (TN);
            Oncovex (TN)
PRODUCT     IMLYGIC (Amgen)
REMARK      ATC code: L01XL02
            Product: D09966<US>
EFFICACY    Antineoplastic, Oncolytic virus
  DISEASE   Melanoma [DS:H00038]
  TYPE      Gene therapy product
COMMENT     Oncolytic herpes simplex virus type 1 (HSV1) expressing GM-CSF [HSA:1437]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01X OTHER ANTINEOPLASTIC AGENTS
                L01XL Antineoplastic cell and gene therapy
                 L01XL02 Talimogene laherparepvec
                  D09966  Talimogene laherparepvec (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Antineoplastics, Other
               Talimogene Laherparepvec
                D09966  Talimogene laherparepvec (USAN)
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D09966
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09966
             Cellular and gene therapy products
              D09966
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09966
DBLINKS     CAS: 1187560-31-1
            PubChem: 124490634
///
